Lindagan, Sayba M.

HRN: 07-62-08  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/22/2025
CEFTRIAXONE 1G (VIAL)
10/22/2025
10/29/2025
IV
2g
OD
UTI
Waiting Final Action 
10/28/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
10/28/2025
10/28/2025
IV
4.5gm
LD
Septicemia
Waiting Final Action 
10/28/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/28/2025
10/28/2025
IV
350mg
Now
Septicemia Sec To CUTI
Waiting Final Action 
10/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/28/2025
11/03/2025
IV
2.25gm
Q8
Septicemia Sec To CUTI
Checking Final Appropriateness 
10/28/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
10/28/2025
11/05/2025
IV
2.25g
Q8h
Complicated UTI
Checking Final Appropriateness 
10/28/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/28/2025
10/28/2025
IV
350mg
Now
Complicated Uti
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: